Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (1351)	2/11/2000 2:50:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

Friday February 11, 2:32 pm Eastern Time Company Press Release SOURCE: Sangamo BioSciences, Inc. Sangamo BioSciences, Inc. Files Registration Statement for Initial Public Offering of Common Stock POINT RICHMOND, Calif., Feb. 11 /PRNewswire/ -- Sangamo BioSciences, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of common stock. All shares will be offered by Sangamo. The offering is being made through an underwriting group managed by Lehman Brothers Inc., Chase H&Q, ING Barings, and William Blair & Company. Sangamo is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off in virtually all organisms by recognizing specific DNA sequences. Our Universal Gene Recognition(TM) technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins, or ZFPs. By engineering ZFPs so the can selectively regulate a target gene, Sangamo has created ZFP transcription factors that can control gene expression and, consequently, cell function. The Company intends to establish Universal Gene Recognition as a broadly-used technology platform for commercial applications in pharmaceutical discovery research, human therapeutics, DNA diagnostics, and agricultural and industrial biotechnology. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. Copies of the prospectus relating to the offering may be obtained from Lehman Brothers Inc., 3 World Financial Center, New York, New York 10285, 212-526-7000; Chase H&Q, One Bush Street, San Francisco, California 94104, 415-439-3000; ING Barings, 667 Madison Avenue, New York, New York 10021, 212-409-7700 or William Blair & Company, 222 West Adams Street, Chicago, Illinois 60606 312-364-8061. SOURCE: Sangamo BioSciences, Inc.